However, recent post hoc analyses from the CANTOS trial (NCT01327846) found that post-myocardial infarction patients treated with Canakinumab required significantly fewer joint replacement surgeries [73], suggesting that the inhibition of IL-1β may be chondroprotective. The gene discussed is IL1B; the disease is myocardial infarction.